News for UroGen Pharma Ltd. (URGN)

U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday. Shares of CEMEX, S.A.B. de C.V. CX rose sharply during Monday's s...

UroGen Pharma (URGN) has released new findings from the OPTIMA II Phase 2b study concerning its UGN-102 intravesical solution. The study reveals that UGN-102 de

UroGen Pharma (URGN) has released promising results from its Phase 3 ENVISION trial concerning UGN-102, an investigational therapy for recurrent low-grade inter

UroGen Pharma (URGN) has released promising safety outcomes from its Phase 1 study of UGN-301, an experimental treatment for recurrent non-muscle invasive bladd

UroGen Pharma Ltd. (URGN) reports nearly four-year duration of response for certain patients treated with JELMYTO. OLYMPUS study finds median response d

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cance

UGN-102 shows promising patient-reported outcomes in clinical trials, indicating no adverse impact on quality of life for LG-IR-NMIBC patients. Studies

UroGen Pharma Ltd. (URGN) announced a median duration of response of two years in its OPTIMA II study for UGN-102. The study involved patients with recu

UroGen Pharma Ltd. (URGN) reports an 80.6% 18-month Duration of Response (DOR) from the Phase 3 ENVISION trial for UGN-102. The investigational treatmen

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cance

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Scotiabank has commenced coverage of UroGen Pharma (URGN), assigning it an Outperform rating and setting a price target of $23. The pharmaceutical company is pi

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cance

UroGen Pharma (URGN) to present key clinical data on urothelial cancer treatments at AUA 2025. Data highlights include results from trials for UGN-102, JELM

Overview of the Recent Transaction On April 20, 2020, Wildcat Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring 6,070,588 shares

Release Date: March 10, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points UroGen Pharma L

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NURGN.OQ - Urogen Pharma LtdQ4 2024 Urogen Pharma Ltd Earnings CallMar 10, 2025 / 02:00PM GMT =

Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the UroGen Pharma Fourth Quarter and Full Year 2024 Earnings Call.

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 - Earnings Conference Call March 10, 2025 10:00 AM ETCompany ParticipantsVincent Perrone - Head of IRLiz Barrett -...